Table 2.
Characteristics of 13 patients with EGFR mutation-positive tumors other than NSCLC
| Case No. | Tumor type | Histology | EGFR aberration (exon) | EGFR mutation sensitive/resistant [10, 12, 39] | Concomitant mutations | EGFR therapy | Best response by RECIST | TTF (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | Adrenocortical | Adrenal cortical carcinoma | Deletion in exon 19 | Sensitive |
PIK3CA: no KRAS: no TP53: H214Y (exon 6) |
– | – | – |
| 2 | Breast | Infiltrating ductal carcinoma | G857E (exon 21) | Sensitive |
PIK3CA: not done KRAS: no TP53: not done |
– | – | – |
| 3 | Parathyroid | Parathyroid carcinoma | G796S (exon 20) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: not done |
Erlotinib | SD | 6 |
| 4 | Carcinoid | Carcinoid tumor | A859T (exon 21) | Possibly resistant |
PIK3CA:H1047R (exon 20) KRAS: no TP53: not done |
– | – | – |
| 5 | Cholangiocarcinoma | Moderately differentiated cholangiocarcinoma | E804K (exon 20) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: not done |
– | – | – |
| 6 | Salivary gland | Poorly differentiated carcinoma of parotid gland | D770N (exon 20) | Resistant |
PIK3CA: no KRAS: no TP53: not done |
Erlotinib, cetuximab, and bevacizumab | PD | 1 |
| 7 | Epiglottis | Poorly differentiated squamous cell carcinoma | H835L (exon 21) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: V157F (exon 5) |
Cetuximab, carboplatin, and paclitaxel | SD | 3 |
| 8 | Ovarian | High-grade papillary serous carcinoma | T751I (exon 19) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: not done |
Erlotinib, cetuximab, and bevacizumab | PD | 4 |
| 9 | Renal | Undifferentiated adenocarcinoma | H773Y (exon 20); deletion in exon 19 | Possibly resistant; sensitive |
PIK3CA: no KRAS: not done TP53: not done |
– | – | – |
| 10 | Thymic | High-grade thymic carcinoma | T785I (exon 20) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: Not done |
– | – | – |
| 11 | Sarcoma | Unclassified sarcoma | V769M (exon 20) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: not done |
– | – | – |
| 12 | Sarcoma | Unclassified spindle cell sarcoma | T751I (exon 19) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: not done |
Erlotinib | PD | 2 |
| 13 | Skin | Basal cell carcinoma | P741S (exon 19) | Sensitivity is unclear |
PIK3CA: no KRAS: no TP53: not done |
Cetuximab, carboplatin, paclitaxel; cetuximab, and sirolimus |
SD; SD | 7; 2 |
EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small-cell lung cancer; PD, progressive disease; PIK3CA, phosphatidylinositol-3-kinase, catalytic, alpha polypeptide; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; TTF, time-to-treatment failure; TP53, tumor protein p53.